Eyeglass frame allergic contact dermatitis: Does tacrolimus prevent recurrences?

Contact Dermatitis

Volumn 53, Issue 4, 2005, Pages 219-221

  Nakada, Tokio ^a   Iijima, Masafumi ^a   Maibach, Howard I ^b  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Allergic contact dermatitis; Eyeglass frame; Tacrolimus ointment

Indexed keywords

ALLERGEN; CORTICOSTEROID; PETROLATUM; TACROLIMUS; VINYL DERIVATIVE;

ADULT; ARTICLE; CASE REPORT; CONTACT DERMATITIS; CORTICOSTEROID THERAPY; ERYTHEMA; EXPOSURE; HUMAN; INFLAMMATION; MALE; OINTMENT; PATCH TEST; PLASTER CAST; RECURRENT DISEASE; SPECTACLES; SYMPTOMATOLOGY;

ADULT; COLORING AGENTS; DERMATITIS, ALLERGIC CONTACT; EYEGLASSES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; OINTMENTS; PATCH TESTS; PHENYLENEDIAMINES; RECURRENCE; TACROLIMUS;

EID: 27144508387     PISSN: 01051873     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0105-1873.2005.00664.x     Document Type: Article

References (14)

1. Sugiura M. Group study with standard allergen series of the Japanese Society for Contact Dermatitis and gold sodium thiosulfate by patch testing in 1999. Environ Dermatol 2002: 9: 105-115.
2. Wilkinson D S, Fregert S, Magnusson B et al. Terminology of contact dermatitis. Acta Derm Venereol 1970: 50: 287-292.
3. Ritchel R L, Fowler J F. Fisher's Contact Dermatitis, 5th edition. Philadelphia: Lippincott Williams & Wilkins, 2001.
4. Nakada T, Maibach H I. Eyeglass allergic contact dermatitis. Contact Dermatitis 1998: 39: 1-3.
5. Doherty E, Freeman S. Spectacle frame dermatitis due to paraphenylenediamine. Australas J Dermatol 1988: 29: 113-115.
6. Bekersky I, Fitzsimmons W, Tanase A, Maher R M, Hodosh E, Lawrence I. Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis. J Am Acad Dermatol 2001: 44: S17-S27.
7. Ruzicka T, Assmann T, Lebwohl M. Potential future dermatological indications for tacrolimus ointment. Eur J Dermatol 2003: 13: 331-342.
8. Alomar A, Puig L, Gallardo C M, Valenzuela N. Topical tacrolimus 0.1% ointment (protopic) reverses nickel contact dermatitis elicited by allergen challenge to a similar degree to mometasone furoate 0.1% with greater suppression of late erythema. Contact Dermatitis 2003: 49: 185-188.
9. Saripalli Y V, Gadzia J E, Belsito D V. Tacrolimus ointment 0.1% in the treatment of nickel-induced allergic contact dermatitis. J Am Acad Dermatol 2003: 49: 477-482.
10. Lauerma A I. Immunomodulation of contact dermatitis. Curr Probl Dermatol 1995: 22: 51-53.
11. Lauerma A I, Maibach H I, Granlund H, Erkko P, Kartamaa M, Stubb S. Inhibition of contact allergy reactions by topical FK506. Lancet 1992: 340: 556.
12. Panhans-Gross A, Novak N, Kraft S, Bieber T. Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol 2001: 107: 345-352.
13. Protopic® ointment, 2002: 0.1% (Tacrolimus hydrate ointment), 4th version; (Fujisawa Pharmaeceutical Co., Ltd).
14. United States of America Food and Drug Administration office of the Commissioner Pediatrics advisory committee sixth meeting 2005, Rockville, Maryland, USA.